| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8814362 | Biological Psychiatry | 2017 | 30 Pages |
Abstract
These findings provide initial evidence of the most effective dose and dose-test interval for future experimental or therapeutic regimens aimed at targeting amygdala functioning using intranasal OXT administration.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Franny B. Spengler, Johannes Schultz, Dirk Scheele, Maximiliane Essel, Wolfgang Maier, Markus Heinrichs, René Hurlemann,